Back to mobile site

Intercept Pharmaceuticals (ICPT) Briefing Docs 'Mostly In-Line' - FBR Capital

April 5, 2016 11:07 AM EDT Send to a Friend
FBR Capital analyst Vernon Bernardino reiterated a Market Perform rating and $192 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login